Navigation Links
Harwood Feffer LLP Announces Investigation of OvaScience, Inc.
Date:9/17/2013

NEW YORK, Sept. 17, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On September 10, 2013, the Company disclosed that it was suspending enrollment in connection with its proprietary technology, Augment, in the U.S. after receiving an "untitled" letter from the FDA "questioning the status of Augment… and advising the Company to file an Investigational New Drug (IND) application."     

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own OvaScience shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
                         (212)935-7400
Email:  bsachsmichaels@hfesq.com
Website:   http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.


'/>"/>
SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
2. Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
3. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
4. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
5. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
7. Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
8. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
9. Plastic Surgeon Dr. Marc J. Salzman Announces Use of Astanza Trinity Laser Tattoo Removal System, Runs Limited-Time Promotion
10. Sam Solakyan announces Paramount Management Services is now a full-scale MSO
11. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017 NuvoAir (formerly called Pond Healthcare ... a partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry ... the leading mobile spirometry platform and Novartis, commitment to address ... ... ...
(Date:9/6/2017)... 2017  Robert G. Szewc, M.D., is recognized by ... recognition of his contributions to the Medical field.      ... at the practice of Kidney and Hypertension Specialists, which ... hypertension solutions. He has worked in this position since ... as well as expertise in kidneys, hypertension, chronic disease ...
(Date:9/6/2017)... 6, 2017 NeuroRx, a clinical stage biopharma company ... Behavior (ASIB), has been granted Fast Track status by the ... NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The ... of this sequential therapy targeting patients who are admitted to ... ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... 25, 2017 , ... FDAnews Expert Insight Series:, Device Regulation ... – 3:00 p.m. ET, http://www.fdanews.com/deviceregulation      , FDA Commissioner Scott ... short months:, ,     The first device recall over cybersecurity (a ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Byron Eaton Agency, ... the central Alabama region, is organizing a local charity drive to send money and ... 11 trillion gallons of water have fallen on Houston as a result of Hurricane ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... the launch of its new website. No need to be concerned about ... answer. Go to welldonedesigns.com where all orders are printed and shipped within 5-10 ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... development and validation of bioassays at two upcoming conferences. , At the BEBPA ...
(Date:9/25/2017)... ... 25, 2017 , ... NCPDP Foundation , a 501(c)(3) ... awarded a $40,000 grant to Johns Hopkins Medicine to address patient safety risk ... to electronically cancel a prescription already submitted to a pharmacy. Studies indicate that ...
Breaking Medicine News(10 mins):